1[1]Thomas C V, Coker M L, Zellner J L, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1998,97:1708-1715.
2[2]Woodiwiss A J, Tsotetsi O J, Sprott S, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation, 2001, 103:155-160.
3[3]Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol, 2000,32:109-120.
4[4]Spinale F G, Coker M L, Heung L J, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 2000,102:1944-1949.
5[5]Fini M E, Cook J R, Mohan R, et al. Regulation of matrix metalloproteinase gene expression. In: Parks W C, Mecham R P, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press, 1998.299-356.
6[6]Vincenti M P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Methods Mol Biol, 2001, 151:121-148.
7[7]Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem, 1993,53:288-295.
8[8]Sameshima T, Nabeshima K, Tpple B P, et al. Glioma cell extracellular matrix metalloproteinases inducer (EMMPRIN) (CD47) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett,2000,157:177-184.
9[9]Woessner J F Jr, Nagase H. Introduction to the Matrix Metalloproteinases (MMPs). In: Matrix Metalloproteinases and TIMPs. New York: Oxford University Press, 2000.1-10.
10[10]Miyamori H, Takino T, Seiki M, et al. Human membrane type-2 matrix metalloproteinase is defective in cell-associated activation of progelatinase A. Biochem Biophys Res Commun, 2000,267:796-800.
